Last updated: September 4, 2026
All Day Allergy D is an extended-release combination of cetirizine hydrochloride and pseudoephedrine hydrochloride, generally marketed as a 24-hour allergy and nasal-congestion product. Its commercial value depends less on active-ingredient exclusivity than on controlled release, tablet robustness, consumer tolerability, OTC compliance, and reliable access to pseudoephedrine.
The principal formulation opportunity is to preserve 24-hour pseudoephedrine delivery while improving swallowability, tablet size, coating performance, lactose-free positioning, and manufacturing efficiency. The product is exposed to generic and private-label competition because its active ingredients are long-established and the product is regulated under the U.S. OTC framework rather than as a conventional new prescription product.
What active ingredients and dosage form does All Day Allergy D contain?
All Day Allergy D products are generally positioned as extended-release tablets containing:
| Component |
Typical strength |
Function |
| Cetirizine hydrochloride |
5 mg |
Second-generation antihistamine |
| Pseudoephedrine hydrochloride |
120 mg |
Nasal decongestant |
| Dosage form |
24-hour extended-release tablet |
Sustained pseudoephedrine exposure |
The product is intended for adults and children aged 12 years and older. The cetirizine component addresses allergy symptoms such as sneezing, rhinorrhea, and itchy or watery eyes. Pseudoephedrine reduces nasal and sinus congestion through vasoconstriction.
The principal technical challenge is combining an immediate-acting antihistamine with a decongestant that requires extended release. The formulation must prevent rapid pseudoephedrine liberation while preserving cetirizine availability and acceptable tablet disintegration behavior.
What excipient strategy supports a 24-hour allergy and congestion tablet?
The most commercially practical strategy is a hydrophilic matrix or coated extended-release system built around cellulose-based polymers.
Release-controlling excipients
Hypromellose is a likely core excipient for controlling pseudoephedrine release. Its hydration creates a gel layer that slows water penetration and drug diffusion. Polymer grade, viscosity, particle size, and concentration determine the release profile.
Other possible release-control materials include:
- Ethylcellulose for a more diffusion-controlled barrier.
- Methacrylate copolymers for pH-sensitive or permeability-controlled release.
- Polyethylene oxide for high-viscosity matrix formation.
- Combination polymer systems that reduce sensitivity to compression force and tablet hardness.
A hydrophilic matrix is generally less complex to manufacture than a multiparticulate pellet system. A coated pellet or layered-tablet architecture can deliver stronger separation between cetirizine and pseudoephedrine but usually increases manufacturing steps, process controls, and cost.
Dilution and compression excipients
Microcrystalline cellulose can provide binding, compactibility, and tablet structure. Lactose monohydrate is commonly used as a filler in oral solid dosage forms, although lactose-free alternatives may create a more attractive consumer proposition.
Potential lactose-free fillers include:
- Mannitol, for a lower-hygroscopicity and premium positioning.
- Dibasic calcium phosphate, for high-density tablets.
- Spray-dried cellulose-lactose systems, where lactose is acceptable in low quantities.
- Isomalt or other polyols for specialty positioning, subject to cost and stability review.
The product has a relatively high total drug load because pseudoephedrine hydrochloride contributes most of the active mass. Excipient selection must therefore support a tablet that is large enough for 24-hour performance but still acceptable for daily swallowing.
Lubricants and glidants
Magnesium stearate can reduce tooling friction but may interfere with wetting and release if over-lubrication occurs. Colloidal silicon dioxide can improve powder flow, particularly where the blend contains fine active particles or high polymer content.
Sodium stearyl fumarate is a potential alternative lubricant where magnesium stearate affects dissolution or interparticle bonding. The substitution may require new compression, dissolution, and stability work.
Coating and appearance excipients
Film coating can reduce dusting, improve swallowability, protect the tablet from moisture, and create brand differentiation. Common coating functions include:
- Hypromellose as a film-forming polymer.
- Titanium dioxide or approved colorants for visual identification.
- Polyethylene glycol or triacetin as plasticizers.
- Talc or equivalent anti-tacking materials.
A coating must not mask a score line or compromise the extended-release mechanism. If the product is designed as a non-scored 24-hour tablet, coating thickness and mechanical durability become more important than dose splitting.
What excipients create the strongest commercial differentiation?
The most defensible differentiation is usually functional rather than cosmetic. A substitute product can use the same active ingredients but still face formulation barriers if it must reproduce the reference product's release profile, tablet performance, and stability.
Lactose-free formulation
A lactose-free version could target consumers who avoid lactose or prefer a simplified excipient profile. The opportunity is commercially credible but limited by the fact that lactose in a tablet is usually present at a low level and does not create a broad medical restriction for most consumers.
A lactose-free claim has greater value when combined with:
- Smaller tablet size.
- Gluten-free positioning where supported by controls.
- Dye-free or low-colorant formulation.
- Clear inactive-ingredient disclosure.
- Direct-to-consumer education on the difference between lactose and milk-protein allergy.
Smaller-tablet architecture
A smaller tablet could improve adherence and consumer acceptance. The principal tradeoff is the need to maintain pseudoephedrine release over 24 hours. Higher-density fillers, more efficient polymer systems, and layered compression may reduce tablet volume.
A smaller product has potential in travel, seasonal allergy, and older-consumer segments, but the design must preserve package labeling that clearly states the extended-release nature of the product.
Lower-irritancy excipient profile
A formulation without sodium lauryl sulfate, unnecessary dyes, or high levels of hydrophobic lubricant could support sensitive-consumer positioning. These changes may improve consumer perception, but they do not automatically establish superior clinical performance.
The commercial claim should focus on formulation attributes that can be documented, such as "dye-free" or "lactose-free," rather than implying improved safety without supporting evidence.
How does All Day Allergy D compare with Zyrtec-D and other combination products?
All Day Allergy D competes most directly with Zyrtec-D and store-brand cetirizine/pseudoephedrine extended-release tablets.
| Product category |
Antihistamine |
Decongestant |
Release profile |
Key commercial issue |
| All Day Allergy D |
Cetirizine |
Pseudoephedrine |
Extended release |
Private-label pricing and pharmacy access |
| Zyrtec-D |
Cetirizine |
Pseudoephedrine |
Extended release |
Brand recognition |
| Claritin-D |
Loratadine |
Pseudoephedrine |
Extended release |
Competes for allergy and congestion users |
| Allegra-D |
Fexofenadine |
Pseudoephedrine |
Extended release |
Non-sedating antihistamine positioning |
| Cetirizine-only products |
Cetirizine |
None |
Immediate release, generally |
Lower price and no pseudoephedrine restrictions |
Cetirizine may create more consumer concern about drowsiness than loratadine or fexofenadine, although it is classified as a second-generation antihistamine. Pseudoephedrine access is the larger commercial constraint because products containing it are subject to federal sales controls in the United States.
The competitive advantage of All Day Allergy D is therefore not a unique active ingredient. It is the combination of recognized cetirizine efficacy, once-daily dosing, congestion relief, and lower private-label pricing.
What FDA regulatory status applies to All Day Allergy D?
All Day Allergy D is an OTC combination product subject to the FDA framework for antihistamine and nasal decongestant products. The FDA's OTC monograph system establishes permitted active ingredients, conditions of use, labeling, and dosage requirements for covered products.
The product must also comply with:
- Drug Facts labeling requirements.
- Current good manufacturing practice requirements.
- Stability and expiration-date substantiation.
- Dissolution and release testing for the extended-release dosage form.
- Tamper-evident packaging requirements where applicable.
- Pseudoephedrine sales restrictions under the Combat Methamphetamine Epidemic Act.
Pseudoephedrine products are generally sold from behind the pharmacy counter or through controlled retail systems. Purchasers are subject to identification, transaction-record, and quantity-limit requirements under federal and state law. These restrictions affect merchandising, inventory control, and e-commerce execution.
What patent and exclusivity risks affect All Day Allergy D?
The active ingredients, cetirizine and pseudoephedrine, are long-established compounds with no meaningful new-molecule exclusivity opportunity for this product category. Commercial protection must therefore come from formulation, manufacturing, packaging, trademark, or distribution advantages.
Orange Book status
An OTC monograph product is not evaluated through the same Orange Book listing model used for prescription drugs approved through a new drug application. A conventional Orange Book patent and Paragraph IV strategy is therefore generally not the principal pathway for challenging or protecting an All Day Allergy D product.
A product-specific NDA could create a different regulatory and patent framework, but standard store-brand All Day Allergy D products are generally positioned as OTC monograph products.
Formulation patents
Potential patentable subject matter could include:
- A specific polymer ratio that produces a defined pseudoephedrine release profile.
- A bilayer or multilayer tablet separating cetirizine and pseudoephedrine.
- A coated-particle system that protects pseudoephedrine from burst release.
- A reduced-size tablet with equivalent 24-hour performance.
- A moisture-stable formulation with a defined impurity profile.
- A manufacturing process that improves content uniformity or compression yield.
The practical strength of these patents depends on claim breadth, prior-art density, dissolution data, and the ability to detect infringement. Broad claims covering ordinary use of hypromellose, microcrystalline cellulose, or magnesium stearate would face substantial validity pressure. Narrow claims tied to specific release curves, polymer grades, or manufacturing parameters may be more defensible but easier to design around.
Manufacturing and trade-secret protection
Manufacturing know-how may provide greater value than a narrowly drafted excipient patent. Relevant trade secrets include:
- Granulation endpoint controls.
- Polymer premixing sequence.
- Compression-force settings.
- Coating parameters.
- In-process dissolution controls.
- Packaging moisture controls.
- Pseudoephedrine reconciliation and inventory procedures.
These controls can reduce batch failures and improve supply reliability without requiring public disclosure.
What commercial opportunities exist for All Day Allergy D?
The strongest opportunities are private-label expansion, formulation simplification, and channel-specific packaging.
Private-label and retailer licensing
Retailers can use an All Day Allergy D-type formulation as a store-brand alternative to Zyrtec-D. The product can be sold through pharmacy chains, mass merchants, club stores, and regional grocers, subject to pseudoephedrine controls.
A manufacturer can create commercial value through:
- Authorized private-label manufacturing.
- Multi-retailer packaging configurations.
- Seasonal production planning.
- Dual sourcing of polymers and fillers.
- Reduced tablet and packaging costs.
- Retailer-exclusive pack counts.
The principal negotiation issue is whether the manufacturer supplies a finished product, a semi-finished tablet, or a complete regulatory and packaging package.
Seasonal and geographic demand
Demand rises during tree-pollen, grass-pollen, ragweed, and indoor-allergen seasons. Regional forecasting should account for climate, pollen patterns, respiratory-virus activity, and state-level pseudoephedrine restrictions.
Inventory planning must avoid both stockouts during allergy peaks and excess inventory after the season. A stable formulation with long shelf life can reduce seasonal working-capital exposure.
Premium excipient positioning
Potential premium variants include:
| Variant |
Consumer proposition |
Technical burden |
| Lactose-free |
Avoids lactose in the inactive-ingredient profile |
Moderate |
| Dye-free |
Simplifies excipient messaging |
Low to moderate |
| Smaller tablet |
Easier swallowing |
High |
| Tamper-evident unit dose |
Travel and pharmacy convenience |
Moderate |
| High-barrier blister |
Moisture and portability protection |
Moderate |
| Two-layer tablet |
Improved component separation |
High |
The strongest near-term opportunity is usually a dye-free or lactose-free private-label version because the changes may be less complex than a new release-control architecture.
What generic launch risks exist?
Generic competition is strong because the active ingredients are established, consumer demand is recurring, and retailers can switch among suppliers. The main barriers are not active-ingredient synthesis or clinical development. They are:
- Demonstrating equivalent extended-release performance.
- Maintaining pseudoephedrine supply and reconciliation controls.
- Meeting OTC labeling requirements.
- Achieving stable tablet hardness and dissolution.
- Securing retailer shelf placement.
- Managing seasonal inventory.
- Avoiding formulation patents or confidential manufacturing restrictions.
A generic product can launch through an OTC monograph pathway if it meets applicable requirements. A Paragraph IV challenge is generally less central than it would be for a prescription NDA product, although patent disputes could still arise if a branded or manufacturer-specific formulation is protected by patents outside the standard monograph framework.
How strong is the excipient-based patent estate?
The likely patent estate is moderate to weak at the broad excipient level and potentially stronger at the narrow process or release-profile level.
| Protection type |
Likely strength |
Commercial value |
| Use of hypromellose alone |
Low |
Limited |
| Specific polymer ratio and release profile |
Moderate |
Meaningful if supported by data |
| Bilayer or coated-particle architecture |
Moderate to strong |
Higher barrier to copying |
| Lactose-free formulation |
Low unless technically distinctive |
Primarily marketing value |
| Manufacturing process |
Moderate as a trade secret |
High operational value |
| Packaging configuration |
Low to moderate |
Useful for channel differentiation |
| Trademark and retail exclusivity |
Moderate |
Important for private label |
The best investment case is a formulation that solves a measurable problem: smaller size, better release consistency, improved moisture stability, or a clearly differentiated excipient profile. A patent that merely recites routine tablet excipients is unlikely to provide durable market protection.
Key Takeaways
- All Day Allergy D is generally a 24-hour cetirizine/pseudoephedrine extended-release tablet.
- The primary formulation challenge is sustained pseudoephedrine release with acceptable tablet size and swallowability.
- Hypromellose, microcrystalline cellulose, lubricants, glidants, and film-coating materials are central to the excipient strategy.
- Lactose-free, dye-free, smaller-tablet, and high-barrier packaging variants offer the clearest commercial opportunities.
- The product has limited active-ingredient exclusivity and faces substantial generic and private-label competition.
- Pseudoephedrine controls are a major commercial constraint, affecting retail access, inventory, and e-commerce.
- Broad excipient patents are likely weak; specific release profiles, multilayer architectures, and manufacturing processes offer stronger protection.
- The strongest business model is private-label or retailer-exclusive supply supported by reliable seasonal manufacturing.
FAQs
Can All Day Allergy D be reformulated without pseudoephedrine?
Yes, but removing pseudoephedrine creates a different product category. A cetirizine-only product would avoid pseudoephedrine sales restrictions but would no longer provide the same congestion-relief positioning.
Is lactose-free All Day Allergy D commercially attractive?
It can be attractive as a differentiated private-label product, particularly when combined with dye-free labeling and transparent inactive-ingredient disclosure. The commercial benefit is likely greater in specialty and direct-to-consumer channels than in highly price-sensitive mass retail.
What excipient is most important for 24-hour performance?
The release-controlling polymer system is usually the most important excipient element. Polymer grade, concentration, particle distribution, compression force, and coating conditions collectively determine pseudoephedrine release.
Can a competitor copy the excipients in All Day Allergy D?
A competitor can generally use the same established excipient classes, but it must independently meet applicable dissolution, stability, quality, and labeling requirements. A specific patented formulation or manufacturing process could restrict copying.
Does All Day Allergy D have biosimilar risk?
No. Biosimilar pathways apply to biological products. All Day Allergy D is a small-molecule oral solid dosage product and faces generic-drug and private-label competition instead.
References
-
U.S. Food and Drug Administration. (n.d.). DailyMed: Cetirizine hydrochloride and pseudoephedrine hydrochloride extended-release tablets labeling. National Library of Medicine.
-
U.S. Food and Drug Administration. (2023). Drug Facts labeling for over-the-counter human drug products. FDA.
-
U.S. Food and Drug Administration. (2024). Nasal decongestant and antihistamine drug products for over-the-counter human use. Code of Federal Regulations, 21 C.F.R. Part 341.
-
U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005. Title VII of the USA PATRIOT Improvement and Reauthorization Act.
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.
